Please login to the form below

Not currently logged in
Email:
Password:

Non-muscle-invasive bladder cancer

This page shows the latest Non-muscle-invasive bladder cancer news and features for those working in and with pharma, biotech and healthcare.

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail

Despite the withdrawal, AZ still has several phase 3 trials testing Imfinzi in various treatment combinations for early- and late-stage bladder cancer. ... This includes the phase 3 NILE trial in metastatic disease, the phase 3 NIAGARA trial in muscle

Latest news

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2015 Deal Watch October 2015

    Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... MCNA for non-muscle invasive bladder cancer  (BLA filed). Licence. 137. Proteros biostructures/ Merck &Co.

  • Achieving consensus

    Their joint aim: to facilitate uniform use of fluorescence cystoscopy in the diagnosis and follow up of bladder cancer, with the ultimate goal of improved care and better outcomes for patients. ... Despite widespread acceptance of the evidence for

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....